Wave Life Sciences Ltd. (WVE)

6,14 +0,26 (+4,42%) Alla chiusura: 04:00PM EDT

Wave Life Sciences Ltd.

Marina One East Tower
7 Straits View No.12-00
Singapore 018936
Singapore
65 6236 3388
https://www.wavelifesciences.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 266

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Paul B. Bolno M.B.A., M.D.	President, CEO & Director	1,13M	N/D	1974
Mr. Kyle B. Moran CFA	CFO & Principal Accounting Officer	726,34k	N/D	1971
Dr. Chandra Vargeese Ph.D.	Chief Technology Officer	731,8k	N/D	1961
Kate Rausch	Head of Investor Relations	N/D	N/D	N/D
Ms. Linda Rockett J.D.	Senior VP & General Counsel	N/D	N/D	N/D
Dr. Christopher Francis Ph.D.	Senior VP of Corporate Development & Head of Emerging Areas	493,13k	4,75M	1978
Ms. Daryn Lewis	Senior VP & Head of Human Resources	N/D	N/D	N/D
Dr. Sridhar Vaddeboina Ph.D.	Senior Vice President of Chemistry, Manufacturing & Controls	N/D	N/D	N/D
Ms. Anne-Marie Li-Kwai-Cheung	Chief Development Officer	N/D	N/D	N/D
Dr. Hsiu-Chiung Yang Ph.D.	Senior Vice President of Translational Medicine	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

Governance aziendale

L'ISS Governance QualityScore di Wave Life Sciences Ltd. al 1 maggio 2024 è 4. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 3; diritti degli azionisti: 3; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.